5 Peritoneal dialysis solutions

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 9, 2005, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMINO ACID; BICARBONATE; CA 125 ANTIGEN; CALCIUM; GLUCAGON; GLUCOSE DEGRADATION PRODUCT; HYALURONIC ACID; ICODEXTRIN; LACTIC ACID; MAGNESIUM; MALTOSE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; POLYMER; PREALBUMIN; TRANSFERRIN;

ALBUMIN BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; BIOCOMPATIBILITY; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; COST BENEFIT ANALYSIS; DIALYSATE; GLUCAGON BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERSENSITIVITY REACTION; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; IN VITRO STUDY; KIDNEY FAILURE; MALNUTRITION; MESOTHELIUM CELL; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; NONHUMAN; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PERITONEUM CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RENAL OSTEODYSTROPHY; TRANSFERRIN BLOOD LEVEL; ULTRAFILTRATION; UREMIA;

EID: 27944509603     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi1119     Document Type: Article

References (73)

1. Wideroe TE, Smeby LC, Myking OL. Plasma concentrations and transperitoneal transport of native insulin and C-peptide in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1984; 25: 82-87 (B)
2. Delarue J, Maingourd C, Couet C, Vidal S, Bagros P, Lamisse F. Effects of oral glucose on intermediary metabolism in continuous ambulatory patients versus healthy subjects. Perit Dial Int 1998; 18: 505-511 (B)
3. Delarue J, Maingourd C, Lamisse F, Garrigue MA, Bagros P, Couet C. Glucose oxidation after a peritoneal and an oral glucose load in dialyzed patients. Kidney Int 1994; 45: 1147-1152 (B)
4. Lindholm B, Bergstrom J. Nutritional management of patients undergoing peritoneal dialysis. In: Nolph KD, ed., Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht; 1989: 230-260 (N.A)
5. Coles GA, Williams JD, Topley N. Peritoneal inflammation and long-term changes in peritoneal structure and function. In: Gokal R, Khanna R, Krediet RT, Nolph KD eds, Textbook of Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht; 2000: 565-584 (N.A)
6. Gotloib L, Shostak A, Waisbrut V, Kushnier R. High glucose induces a hypertrophic, senescent mesothelial cell phenotype after long in vivo exposure. Nephron 1999; 82:164-173 (N.A.)
7. Nakayama M, Kawaguchi Y, Yamada K et al. Immunohistochemical detection of advanced glycosylation end product in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186 (B)
8. Park MS, Lee HA, Chu WS, Yang DH, Hwang SD. Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 2000; 20: 452-460 (B)
9. Friedlander M, Wu Y, Schulak J, Monnier V, Hricik DE. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25: 445-451 (B)
10. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9: 41-45 (B)
11. Zweers MM, Splint LJ, Krediet RT, Struijk DG. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16: 651-654 (N.A.)
12. Mateijsen MAM, van der Wal AC, Hendriks PMEM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525 (B)
13. Williams JD, Graig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479 (B)
14. Hendriks PMEM, Ho-dac-Pannekeet MM, Van Gulik TM et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors and peritoneal transport kinetics. Perit Dial Int 1997; 17: 136-143 (B)
15. Davies SJ, Philips L, Naish PF, Russel GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046-1051 (C)
16. Wieslander AP, Andren AHG, Nilsson-Thorell C, Muscalu N, Kjellstrand PTT, Rippe B. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995; 15: 348-352 (N.A.)
17. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int 1995; 15: 158-164 (N.A)
18. Witowski J, Bender TO, Wisniewska-Elnur J et al. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003; 23: 381-390 (N.A.)
19. Schalkwijk CG, ter Wee PM, Teerlink T. Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-bufferd peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids. Perit Dial Int 2000; 20: 796-798 (N.A.)
20. Tauer A, Knerr T, Niwa T et al. In vitro formation of N (epsilon)-C(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280: 1408-1414 (N.A.)
21. Witowski J, Korybalska K., Ksiazek K et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004; 19: 917-924. (N.A)
22. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357 (A)
23. Jones S, Holmes CJ, Krediet RT et al. Bicarbonate/lactate based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-1538 (A)
24. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418 (A)
25. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21: 560-567 (N.A.)
26. Mistry CD, Gokal R. Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis?: The role for 'colloid' osmosis. Clin Sci 1993; 85: 495-500 (B)
27. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2: 178-182 (B)
28. Mistry CD, Gokal R, Peers EM, and the MIDAS study group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994; 46: 496-503 (A)
29. Wolfson M, Piraino B, Hamburger RJ, Morton AR, and the Icodextrin Study Group. A randomised controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40: 1055-1065 (A)
30. Ho-dac-Pannekeet MM, Schouten N, Langedijk MJ et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50: 979-986 (B)
31. 2-microglobulin in continuous ambulatory peritoneal dialysis: Influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol Dial Transplant 1990; 5: 13-19 (B)
32. Posthuma N, ter Wee PM, Verbrugh HA et al. Icodextrin instead of glucose during the daytime dweil in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12: 550-553 (A)
33. Imholz ALT, Brown CB, Koomen GCM, Arisz L, Krediet RT. The effect of glucose polymers on water removal and protein clearances during CAPD. Adv Perit Dial 1993; 9: 25-30 (B)
34. Gokal R, Mistry CD, Peers EM and the MIDAS study group. Peritonitis occurrence in a multicentre study of icodextrin and glucose in CAPD. Perit Dial Int 1995; 15: 226-230 (B)
35. Wilkie ME, Plunt MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997; 17: 84-87 (B)
36. Davies S, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomised controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344 (A)
37. Konings CJAM, Koomen JP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomised study. Kidney Int 2003; 63: 1556-1563 (A)
38. Wens R, Taminne M, Devriendt J et al. A previously undescribed side effect of icodextrin. Overestimation of glycaemia by glucose analyser. Perit Dial Int 1998; 18: 603-609 (A)
39. Schoenicke G, Grabensee B, Plum J. Dialysis with icodextrin interferes with measurement of serum amylase activity. Nephrol Dial Transplant 2002; 17: 1988-1992 (A)
40. Wilkie ME, Brown CB. Polyglucose solution in CAPD. Perit Dial Int 1997; 17 [Suppl 2]: S47-S50 (N.A.)
41. Goldsmith D, Jayawasdene S, Sabhaswol N, Conney K. Allergic reactions to polymeric glucose-based PD fluid icodextrin in patients with renal failure. Lancet 2000; 355: 897 (N.A.)
42. Queffeulou G, Lebrun-Vignes B, Wheatley P, Montagnac R, Mignon F. Allergy to icodextrin. Lancet 2000; 356: 75 (N.A.)
43. Devino Fiho JC. Allergic reactions to icodextrin in patients with renal failure. Lancet 2000; 355: 1365 (N.A.)
44. Martin J, Sansone G, Cirugeda A, Sanchez-Tomero JA, Munoz C, Selgas R. Severe peritoneal mononucleosis associated with icodextrin use in continuous ambulatory peritoneal dialysis. Adv Perit Dial 2003; 19: 191-194 (N.A.)
45. Toure F, Lavaud S, Mohajer M et al. Icodextrin-induced peritonitis: study of live cases and comparison with bacterial peritonitis. Kidney Int 2004; 65: 654-660 (N.A.)
46. Tintillier M, Pochet JM, Christophe JL, Scheiff JM, Goffin E. Transient sterile chemical peritonitis with icodextrin: Clinical presentation, prevalence, and literature review. Perit Dial Int 2002; 22: 534-537 (N.A)
47. Kopple JD, Bernard D, Messana J et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47: 1148-1157 (B)
48. Faller B, Aparicio M, Faict D et al. Clinical evaluation of an optimized 1.1% amino acid solution for peritoneal dialysis. Nephrol Dial Transplant 1995; 10: 1432-1437 (B)
49. Jones M, Hagen B, Boyle CA et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. Am J Kidney Dis 1998; 32: 761-769 (A)
50. Arfeen S, Goodship THJ, Kirkwood A, Ward MK. The nutritional/metabolic effects of 8 weeks of continuous ambulatory peritoneal dialysis with 1.1% amino acid solution. Clin Nephrol 1990; 33: 192-199 (B)
51. Kwong MBL, Lee JSK, Chan MK. Transperitoneal calcium and magnesium transfer during an 8-hour dialysis. Perit Dial Bull 1987; 7: 85-89 (B)
52. Davenport A, Goel S, MacKenzie JC. Audit of the use of calcium carbonate as phosphate binder in 100 patients treated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1992; 7: 632-635 (B)
53. Locatelli F, Cannata-Andia JB, Drueke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17: 723-731 (N.A)
54. Hutchison AJ, Freemont AJ, Boulton HF, Gokal R. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7: 1219-1225 (B)
55. Johnson DW, Rigby RJ, McIntyre HB, Brown A, Freeman J. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients. Nephrol Dial Transplant 1996; 11: 88-93 (A)
56. Weinreich T, Passlick-Deetjen J, Ritz E, collaborators of the peritoneal dialysis multicenter study group. Low dialysate calcium in continuous ambulatoryv peritoneal dialysis: A randomized controlled multicenter trial. Am J Kidney Dis 1995; 25: 452-460 (A)
57. Buijsen CGM, Struijk DG, Huijgen AJ, Boeschoten EW, Wilmink JM. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients? Perit Dial Int 1996; 16: 497-504 (B)
58. Nolph KD, Prowant B, Serkes KD et al. Multicentric evaluation of a new peritoneal dialysis solution with a high lactate and low magnesium concentration. Perit Dial Bull 1983; 3: 63-65 (B)
59. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renai disease. Kidney Int 1987; 32: 388-394 (C)
60. Navarro JF, Mora C, Macia M, Garcia J. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients. Perit Dial Int 1999; 19: 455-461 (B)
61. Seeling M. Electrocardiographic patterns of magnesium depletion appearing in alcoholic heart disease. Ann NY Acad Sci 1969; 162: 906-917 (C)
62. Hollifield J. Magnesium depletion, diuretics and arrhythmias. Am J Med 1987; 82 [Suppl 3A]: 30-37 (C)
63. Ejaz AA, McShane AP, Gandhi VC, Leehey DJ, Ing TS. Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution. Perit Dial Int 1995; 15: 61-64 (C)
64. Reaich D, Channon SM, Scrimgeour CM, Daley SE, Wilkinson R, Goodship THJ. Correction of acidosis in humans with chronic renal failure decreases protein degradation and amino acid oxidation. Am J Physiol 1993; 265: E230-E235 (B)
65. Stein A, Moorhouse J, Iles-Smith H et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997; 52: 1089-1095 (A)
66. Feriani M. Buffers: Bicarbonate, lactate and pyruvate. Kidney Int 1996; 50 [Suppl 156]: S75-S80 (B)
67. Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J, and the Bicarbonate CAPD operative Group. A randomized multicenter long-term clinical study comparing a bicarbonate buffered CAPD solution with the standard lactate buffered CAPD solution. Kidney Int 1998; 54: 1731-1738 (A)
68. Coles GA, Gokal R, Ogg C et al. A randomized controlled trial of a bicarbonate and a bicarbonate/lactate containing dialysis solution in CAPD. Perit Dial Int 1997; 17: 48-51 (A)
69. Mactier RA, Sprosen TS, Gokal R et al. Bicarbonate and bicarbonate/ lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53: 1061-1067 (A)
70. Bazilinsky NG, Dunea G, Ing TS. Treatment of metabolic alkalosis in renal failure. Int J Artif Organs 1987;10: 284-286 (N.A.)
71. Tattersall JE, Dick C, Doyle S, Greenwood RN, Farrington K. Alkalosis and hypomagnesaemia: Unwanted effects of a low-calcium CAPD solution. Nephrol Dial Transplant 1995; 10: 258-262 (B)
72. Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: Role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002; 13: 480-489 (N.A.)
73. Mortier S, De Vriese AS, McLoughlin RM et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14: 1296-1306 (N.A.)